These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21604586)

  • 1. [Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
    Wepner U
    MMW Fortschr Med; 2011 May; 153(18):20-1. PubMed ID: 21604586
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
    Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
    [No Abstract]   [Full Text] [Related]  

  • 3. [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1].
    Oyagüez I; Casado MA; Cotarelo M; Ramírez-Arellano A; Mallolas J
    Farm Hosp; 2009; 33(5):247-56. PubMed ID: 19775575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
    Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
    Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
    Rosso R; Di Biagio A; Maggiolo F; Nulvesu L; Callegaro AP; Taramasso L; Bruzzone B; Viscoli C
    AIDS Care; 2012; 24(1):54-8. PubMed ID: 21800951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
    Cooper V; Moyle GJ; Fisher M; Reilly G; Ewan J; Liu HC; Horne R;
    AIDS Care; 2011 Jun; 23(6):705-13. PubMed ID: 21476152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
    Pujari S; Dravid A; Gupte N; Joshi K; Bele V
    Medscape J Med; 2008; 10(8):196. PubMed ID: 18924648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of a fixed-dose combination of Efavirenz-Emtricitabine-Tenofovir in a tertiary hospital].
    Padullés-Zamora N; Figueras-Suriol A; Comas-Sugrañes D; Jodar-Masanes R
    Farm Hosp; 2010; 34(6):312-4. PubMed ID: 20418139
    [No Abstract]   [Full Text] [Related]  

  • 11. No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.
    Burger D; van Luin M; Bosch M; van der Ven A; Brouwer AM; Keuter M; Dofferhoff T; Koopmans PP
    J Acquir Immune Defic Syndr; 2010 Aug; 54(5):e12-3. PubMed ID: 20647821
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
    AIDS Alert; 2009 Oct; 24(10):119-20. PubMed ID: 20034141
    [No Abstract]   [Full Text] [Related]  

  • 13. Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine.
    Amoroso A; Gilliam BL; Talwani R; Boyce C; Redfield RR; Davis CE
    HIV Clin Trials; 2009; 10(5):320-3. PubMed ID: 19906624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
    Goicoechea M; Best B
    Expert Opin Pharmacother; 2007 Feb; 8(3):371-82. PubMed ID: 17266471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
    Goodman DD; Zhou Y; Margot NA; McColl DJ; Zhong L; Borroto-Esoda K; Miller MD; Svarovskaia ES
    AIDS; 2011 Jan; 25(3):325-33. PubMed ID: 21157296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract]   [Full Text] [Related]  

  • 17. [HIV therapy and adherence].
    Kuhlmann B
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():62-3. PubMed ID: 19024920
    [No Abstract]   [Full Text] [Related]  

  • 18. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
    Bangsberg DR; Ragland K; Monk A; Deeks SG
    AIDS; 2010 Nov; 24(18):2835-40. PubMed ID: 21045636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
    Gazzard BG
    Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
    Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
    J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.